MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology and acute care. MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.

Our most recent press releases

01/18/2008
MGI PHARMA Announces Results from Study Involving the Dual Implantation of Gliadel(R) Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme

01/07/2008
Notice of Correction to Notice of Conversion Right for Senior Subordinated Convertible Notes Due 2024

01/03/2008
MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules Accepted for Review by U.S. FDA